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ABSTRACT
There is an urgent need for novel treatments for Candida infections. The utility of antimicrobial
peptides for antifungal therapy has garnered interest in recent years. One promising family of
peptides is the Histatins, a family of naturally-occurring peptides secreted into the oral cavity
that display antimicrobial activity. Histatin 5 is a twenty-four amino acid peptide with strong
antifungal activity. Studies from our laboratory have identified a small histatin-derived peptide,
KM29, that yields fungicidal activity 10-fold greater than Histatin 5 against multiple Candida
species. Our laboratory has focused on understanding the mechanism of action of KM29 to
further develop it as a therapeutic agent for oral and systemic candidiasis. To this end, a genetic
screen was carried out using the available genome-wide deletion collection in S. cerevisiae. Our
goal was to use this as a subrogates species to learn about the killing mechanism used by KM29
in Candida species. Analysis of the mutants revealed a significant presence of genes involved in
mitochondrial function conferring increased resistance to KM29. We hypothesized that the S.
cerevisiae mutants affected in different aspects of mitochondrial function will be more resistant
to KM29 either because there is less ROS production due to their defective mitochondria, or less
ATP production, which in turn may decrease peptide uptake and/or mitochondrial localization.
We observed concentration dependent ROS production after exposure to KM29, however, this
ROS production was loosely correlated with cell death. We also observed mitochondrial
membrane potential depolarization and mitochondrial fission after exposure to KM29, indicating
impairment of mitochondrial function. Additionally, we observed that the respiratory status of
yeast cells inversely regulates KM29 fungicidal activity by influencing KM29 uptake. In
conclusion, these studies provide valuable insights into the mechanism of action of KM29 and of
cationic peptides in general.
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LITERATURE REVIEW
Candidiasis
Due to advances in healthcare causing more people to be at-risk for fungal infections, the
frequency these infections has increased, making this a growing human health concern. Most
fungal infections are caused by Candida, Aspergillus, or Cryptococcus species of fungi, with
Candida species being the most prevalent causative agents of mycoses-related infections (1, 2).
The genus Candida contains approximately 150 different species, with approximately 18 being
medically relevant (2). As harmless commensals, Candida species constitute part of the normal
human flora, often residing as a commensal in the gut, genitourinary tract, and skin (2). Usually,
Candida-related opportunistic mycoses arise from conditions of reduced immune function or
imbalanced bacterial microflora (2). Diseases caused by Candida species can range from
mucosal infections to bloodstream infections, with the former occurring much more frequently
(3). Although there are several clinical manifestations, mucosal candidiasis is often characterized
by white plagues occurring on mucosal surfaces (4, 5). The exception to this is vulvovaginal
candidiasis that has unique clinical manifestations (3). Clinical manifestations of systemic
candidiasis vary greatly as Candida species have the potential to infect nearly every organ which
results in different presentations based on what organ becomes infected (6-9). Although
occurring less frequently, systemic candidiasis is perceived as the more threatening human health
concern due to the associated high mortality rate. Candida species infections are the fourth most
common cause of nosocomial bloodstream infections in the US and have attributable mortality
rates estimated to be between 15% and 49% (10-12). Additionally, systemic candidiasis
infections cause significant financial burdens. In 2002, it was estimated that financial costs
resulting from systemic candidiasis cases amounted to $1.7 billion in the US alone (13). It is
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recognized that the most common cause of all forms of candidiasis is C. albicans, causing 90%
of vulvovaginal candidiasis cases and 50 to 60% of systemic candidiasis cases (14-16). Likewise,
Candida species are often subdivided into two classes: Candida albicans and non-albicans
Candida (NAC) species. Medically relevant NAC species include C. glabrata, C. parapsilosis,
and C. tropicalis (2).
Candida albicans
C. albicans is a diploid, opportunistic pathogen. As stated above, C. albicans in the most
common cause of all forms of candidiasis. Interestingly, this may be associated with the relative
frequency that C. albicans is isolated from human subjects. In various studies, it has been shown
that 30 to 60% of healthy human subjects carry C. albicans in their microflora (17). Various sites
from which C. albicans has been isolated include: oral mucosa, vaginal mucosa, the gut, and the
skin (2, 17, 18). Due to the diploid genome, it has been difficult to study using traditional genetic
approaches, however, much has been clarified regarding the pathogenicity and virulence factors
of C. albicans.
It comes to no surprise that C. albicans has a vast array of virulence factors given its
ability to infect a wide range of locations and induce many different clinical manifestations.
Some of its virulence factors include: dimorphism, secretion of adhesins and invasins, formation
of biofilms, and secretion of hydrolytic enzymes (19).
C. albicans is a dimorphic fungus that can grow as either budding yeast or true hyphae
(20). The morphogenetic switch between these two forms is regulated by several environmental
cues such as pH, starvation, the presence of serum, temperature, and CO2 (21). Although both
forms of C. albicans have shown to be pathogenic, the transition to hyphae is believed to be
crucial for pathogenicity (2). Two independent studies showed that infections caused by non-
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filamentous C. albicans had reduced lethality (22, 23). Additionally, C. albicans hyphae has
shown to be more invasive than the yeast form (20).
Another virulence factor of C. albicans is the secretion of adhesins and invasins.
Adhesins are cell wall proteins that confer C. albicans the ability to adhere to surfaces or host
cells, while invasins induce engulfment of the organism (24). Although secretion of adhesins is
not a novel process with the genus Candida, it is important to note that C. albicans has been
reported to have greater adherence than other Candida species (25, 26). Interestingly, several of
the seemingly most important adhesins for C. albicans ability to adhere to surfaces are hyphae
specific. The most notable genes implicated in adherence include those from the agglutinin-like
sequence (ALS) gene family (27, 28). Eight members make up this family, with Als3 being
implicated the most in adherence to host cells (28, 29). Another hyphae specific adhesin
important for adherence is Hwp1 (28, 30). Apart from the hyphae specific proteins, numerous
non-hyphae specific proteins have been implicated in adherence, including: Eap1, Iff4, Ecm33,
Mp65, Phr1, Sap9, Sap10, and Int1 (31, 32).
Additionally, C. albicans secretes various invasins that can trigger both passive
(endocytosis) and active (penetration) entry into host cells (31-34). Two proteins implicated in
triggering passive engulfment of C. albicans into host cells include Als3 and Ssa1 (29, 35).
Studies have shown that independent deletions of these result in reduced adherence and invasion
(32, 35). In contrast, the molecular mechanisms regulating active penetration have yet to be
clarified (19).
The colloquial definition of a biofilm is a “surface-associated microbial community
surrounded by an extracellular matrix” (36). Biofilms can form on both abiotic (biomedical
devices for example) and biotic (host cell) surfaces (19). Biofilm formation is a very relevant
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topic in the fields of clinical microbiology and drug resistance. It is estimated that 80% of all
microbial infections are caused by biofilms (37). Additionally, with the advent and more
frequent use of biomedical devices such as pacemakers and catheters, it is particularly troubling.
With regards to C. albicans, biofilm formation is of particular concern due to the azole
antifungal resistance that is commonly associated with it (36, 38). Various explanations, such as
changes in membrane composition, changes in cell wall composition, expression of multidrug
resistance pumps, and presence of persister cells, have been proposed to explain the associated
azole resistance with biofilm formation (36). Biofilm formation in C. albicans is commonly
described as a progression through four distinct steps: substrate adherence, biofilm initiation,
biofilm maturation, and biofilm dispersal. This progression is regulated by complex genetic
pathways involving many genes encoding for various transcription factors and cell wall proteins
(36).
Although there are several other virulence factors that aid in C. albicans pathogenicity,
the last that will be discussed is the secretion of hydrolytic enzymes. Secretion of hydrolytic
enzymes by C. albicans is thought to not only function in degrading host substrates relevant for
the immune response, but also aid in acquisition of nutrients (39, 40). The secreted hydrolytic
enzymes can be grouped into three classes: proteases, lipases, and phospholipases (19).
The protease class of secreted hydrolytic enzymes is largely made up of the secreted
aspartic proteases (SAP) family (19). Ten members constitute this family and can further be
broken down into three groups, each group associated to a particular form of candidiasis (40).
Deletion of these members results in varying forms of reduced pathogenicity in animal infection
models (41, 42).
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C. albicans has ten lipase genes and four different classes of phospholipases (43, 44).
Studies have shown that deletion of genes from both classes of enzymes results in significant
reduction of pathogenicity, supporting their role as virulence factors (45, 46).
As stated before, Candida species infections are the fourth most common cause of
nosocomial bloodstream infections in the US, with C. albicans being the most frequent cause
(11, 47). With advances in healthcare and an increase in population of people with risk factors,
the frequency of Candida related infections are on the rise (2). As a growing human health
concern, it is imperative that more resources be funneled into studying C. albicans and the other
medically relevant Candida species.
Non-albicans Candida species
Although C. albicans predominates among the species of Candida that can cause
infection, there are other Candida species that impact human health. The most medically relevant
non-albicans Candida (NAC) species include C. glabrata, C. parapsilosis, and C. tropicalis (2).
To highlight the relevancy of these organisms, it is estimated that ~90% of all Candida related
bloodstream infections are caused by C. albicans and the three NAC species mentioned (16).
Among all the Candida species, C. glabrata is the second most common species isolated
in systemic candidiasis cases in the US, making this organism the most common species among
all NAC species (47). C. glabrata is an opportunistic fungus most commonly isolated from the
oral cavity (48). This organism has a haploid genome and is traditionally viewed as being more
closely related to S. cerevisiae than other medically relevant Candida species (49). The haploid
genome of C. glabrata, as well as its emergence as a significant fungal pathogen makes it an
enticing organism to study.
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In contrast to C. albicans, C. glabrata is not dimorphic and only grows as yeast cells (2).
This is interesting due to the relative importance of the yeast-hyphae switch in C. albicans
pathogenicity, however, this may denote the distant relation between the two. Relating to this, C.
glabrata does not express hyphae specific adhesins but instead utilizes the EPA gene family that
encodes for non-hyphae specific adhesins (50). Similar to C. albicans, C. glabrata is able to
form biofilms which may reflect its propensity of being isolated from dentures (51).
Additionally, C. glabrata secretes yapsin proteases, which share similarities with SAP9 and 10
proteases (52). Yapsin proteases are important for C. glabrata pathogenicity and survival in the
host, as studies have shown deletion of genes encoding these proteases reduces survival in
macrophages (53).
Of particular clinical importance is the drug resistance often associated with C. glabrata
infections. Various clinical isolates of C. glabrata demonstrating resistance to azoles,
caspofungin, or polyenes have been recovered (54-56). Not only does C. glabrata have intrinsic
resistance to azoles but various mechanisms contributing to significant azole resistance have
been identified (2). Although the increase in C. glabrata isolated from candidiasis infections is
believed to be due to wide-spread use of fluconazole, there is debate whether this increase has
been exacerbated by improvements in identification methods (57, 58).
The second most common NAC species isolated in systemic candidiasis cases in the US
is C. parapsilosis (47). In different regions of the world, C. parapsilosis is the second most
common Candida species isolated in Candida related bloodstream infections (59). Bloodstream
infections caused by this organism have shown to have mortality rates ranging from 4 to 45%
(60, 61). Furthermore, C. parapsilosis is the second most common Candida species isolated in
Candida related bloodstream infections originating in NICUs (62). C. parapsilosis is a diploid
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pathogenic fungus that can grow as yeast cells or pseudohyphae (63). C. parapsilosis can be a
part of the normal human flora, often isolated from the skin, nails, and hands, but it can also be
found in soil, natural sources of water, and domestic animals (63-65). Additionally, C.
parapsilosis is often isolated from medical devices and thus is a common cause of nosocomial
infections (65). Unlike most Candida infections arising from endogenous sources, infections
caused C. parapsilosis arise from exogenous sources (66). Although the pathogenicity and
virulence factors of this organism haven’t been as extensively studied as they have been in C.
albicans, it is known that biofilm formation is important for C. parapsilosis virulence (63). Also,
various SAP gene family proteases have been identified in this organism (67). In general,
antifungal resistance isn’t an issue with C. parapsilosis, although isolated incidents of
amphotericin B and azole resistance have been reported (68, 69).
The fourth most common cause of systemic candidiasis in the US is C. tropicalis,
however, it is the second most common cause of systemic candidiasis in Latin America and the
Asia-Pacific region (59). Additionally, the majority of bloodstream infections caused by this
organism arise from hematologic malignancies (62). C. tropicalis is a diploid opportunistic
pathogen that constitutes part of the normal human flora (2, 70). This organism is able to grow as
yeast cells or true hyphae. The ability to grow as true hyphae is a significant virulence factor,
similar to C. albicans, and because of this, C. tropicalis is believed to be one of the most virulent
NAC species (70). An additional virulence factor of C. tropicalis includes the secretion of
hyphae specific adhesins, encoded by the ALS and HWF genes (71, 72). Aiding in its virulence,
C. tropicalis secretes SAP proteases and is able to form biofilms (70, 73). Similar to C.
parapsilosis, incidents of azole and amphotericin B resistance have been reported in C. tropicalis
(70, 74).
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As stated above, it is estimated that ~90% of all Candida related bloodstream infections
are caused by C. albicans, C. glabrata, C. tropicalis, and C. parapsilosis (16). Additionally, even
though C. albicans is main cause of all candida related infections, the frequency of isolation
from infections of most of the NAC species has increased (16). Furthermore, C. glabrata and C.
parapsilosis have been isolated from bloodstream infections occurring after specific medical
procedures at a frequency that rivals, and sometimes surpasses, the frequency that C. albicans is
isolated in those incidents (62). These data, as well as the reported incidents of antifungal
resistance in the NAC species, denote the medical importance of these organisms and the need to
develop new antifungals.
Emerging Candida species: Candida auris
Adding to the medical relevancy of Candida species is the recently emerging fungal
pathogen, Candida auris. This species was first isolated in 2009 from an ear infection of a
patient in Japan (75). Since then, cases involving infections caused by this species have arisen
around the globe, including in locations such as Korea, Kuwait, Germany, Brazil, South Africa,
and several others (76-80). Additionally, there have been several cases in the US (81).
Interestingly, the seemingly explosive emergence of this species throughout many different
continents is thought to be due to four different clades simultaneously emerging (82).
Various characteristics of this species have been elucidated in the recent years. Candida
auris is positive for biofilm formation, and only some of the strains are positive for
phospholipase and proteinase production (83, 84). This species is similar to C. parapislosis due
to its ability to cause exogenous nosocomial infections (84). The most alarming characteristic
however, is the drug resistance observed in C. auris strains. Studies have shown that C. auris
strains have considerably high fluconazole resistance (85, 86). Although echinocandins seem to
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be effective against this species, the cost and availability of these compounds may make their use
limited (80).
Current antifungal therapies
The therapeutic agents used to treat superficial and systemic candidiasis are mainly
limited to three classes of compounds: the polyenes, azoles, and echinocandins (87). The first
major antifungal breakthrough came in 1953 with the discovery of Amphotericin B, a broadspectrum antifungal in the polyene class of compounds (88). In 2006 two new antifungals were
approved, posaconazole and anidulafungin (87, 88). Posaconazole is an azole antifungal that is
active against Zygomycetes and anidulafungin is an echinocandin class antifungal with good
activity against most Candida species (88).
As stated above, the first class of antifungals to be discovered were the polyenes.
Amphotericin B deoxycholate is the only compound in this class that has been clinically
approved to treat Candida infections (87). This compound has good activity against most
Candida species, with minimal inhibiting concentration values (MIC90) ranging from 0.12-4 (88,
89). The exception to this is against C. krusei, a NAC species, with the MIC90 value ranging
from 0.5-8 (88, 89). Amphotericin B works by binding to ergosterol, a fungi specific cell
membrane component, causing the formation of pores in the cell membrane and leading to cell
death (90, 91). This compound also doesn’t have any major drug-drug interactions, unlike many
of the other commonly used antifungals (88). The major drawback of Amphotericin B, however,
is its drug toxicity towards patients; it has been known to induce renal toxicity and damage. It is
estimated that ~50% of patients who receive Amphotericin B as a therapeutic agent will
experience adverse effects in the form of electrolyte abnormalities or renal damage (92). Due to
the relative effectiveness of this compound against various Candida species, efforts have been
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made to decrease the drug toxicity, most notably through the use Amphotericin B: lipid
formulations. The major drawback of this, however, is cost (87, 93). Drug toxicity aside,
Amphotericin B is the first choice for treatment for neonates with systemic candidiasis and for
pregnant patients (88, 94).
The next class of compounds in the antifungal arsenal, and the most widely used, is the
azoles (95). The first azole to be approved for treatment of fungal infections was miconazole,
with many others being synthesized and approved since then, most recently posaconazole (87,
88). The four major compounds in this class include: fluconazole, itraconazole, posaconazole,
and voriconazole. However, there are many other azoles available for use such miconazole,
ketoconazole, and others (88).
This class is known for the presence of five-membered aromatic rings containing nitrogen
atoms and the two subclasses of azoles are differentiated by the number of nitrogen atoms
present (96). This structure is intimately related to the function and mechanism of action of this
class of compounds as the nitrogen atoms have the propensity to bind to the heme group of
cytochrome P450 14α-demethylase (87). This enzyme is encoded by ERG11 and is vital to the
production of ergosterol, thus binding inhibits ergosterol biosynthesis (98). Subsequent to
inhibition of ergosterol biosynthesis, cell growth is halted (99). It is important to note the
fungistatic, rather than fungicidal, nature of azoles, as this characteristic could allow for drug
resistance (98).
Compounds within this class have differing spectra of activity; voriconazole and
posaconazole have effective activity against all the most medically relevant Candida species,
while fluconazole and itraconazole are effective against all except C. glabrata and C. krusei (88,
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100, 101). This is demonstrated by the various MIC90 values for these drugs against Candida
species.
One of the major drawbacks of this class of compounds are the various drug-drug
interactions they display, making it imperative for patients to review their prescriptions before
receiving antifungal therapy (88). All four major compounds within the azole class interact
negatively with antiarrhythmics, antipsychotics, and migraine medications, thus combinations of
these are suggested against (88). Also, three of the four major compounds interact negatively
with immunosuppressants (88). Another drawback of azole therapy is the accompanied drug
toxicity. Azole therapy has been shown to induce rashes, headaches, gastrointestinal
complications, and hepatotoxicity (102, 103). Additionally, azole therapy has been shown to
cause birth defects, hence why Amphotericin B is the preferred antifungal for pregnant women
(104) .
In most instances, fluconazole is the first choice for treatment for all forms of candidiasis.
This is mainly due to the other azole compounds not conferring significant advantages over
fluconazole in certain manifestations of candidiasis (88). However, fluconazole can be readily
replaced by the other azoles if the patient’s infection is at risk of developing fluconazole
resistance or being fluconazole-refractory (88, 94).
The final class of commonly used antifungal compounds are a group of semisynthetic
lipopeptides called echinocandins (105). Three clinically approved compounds constitute this
class: caspofungin, micafungin, and anidulafungin (106). The advent of this class is relatively
recent, with the first echinocandin being discovered in the 1970s and the first echinocandin being
approved for clinical use, caspofungin, in 2001 (87). Anidulafungin was the last echinocandin
approved, in 2006 (Roemer, 2014). All three compounds of this class display effective activity
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against all the medically relevant Candida species besides C. parapsilosis (88). These
compounds also have similar activity to each other, with the MIC90 values ranging from .03-4
across the top four medically relevant Candida species for all three compounds (107).
These compounds function by inhibiting β-1,3 glucan synthase, thus inhibiting β-1,3
glucan synthesis. β-1,3 glucan is an essential cell wall component of pathogenic yeast and
inhibiting the biosynthesis of this molecule results in cell death (108). These compounds have
few drug-drug interactions and drug toxicity problems (88). They are believed to interact with
various immunosuppressants, but the resulting effects are mild. Likewise, adverse effects due to
echinocandin administration are rare and mild (88).
Various experiments have shown that echinocandin compounds are at least as effective as
Amphotericin B and fluconazole (109, 110). Additionally, fewer adverse effects are associated
with echinocandin administration compared to these two. Because of this, recent guidelines for
treatment of systemic candidiasis are straying away from recommending fluconazole as the first
choice for treatment and instead are recommending echinocandins (94).
As stated above, the antifungal arsenal is limited to three classes of compounds: the
polyenes, azoles, and echinocandins (87). Each class has limitations based on drug toxicity,
drug-drug interactions, cost, and effectiveness against certain Candida species. Considering the
small number of antifungals available and the limitations of each class, it is imperative new
antifungals be developed.
Drug resistance in Candida species
Drug resistance is a common concern in all clinical microbiology fields. For fungal
infections caused by Candida species, it is particularly concerning due to the increase in
frequency of infections caused by innately fluconazole resistant Candida species, C. glabrata
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and C. krusei, and the increase in isolation frequency of fluconazole resistant Candida species
(88, 107). Between 2001 and 2007, the in vitro resistance to fluconazole increased for four
Candida species, including C. albicans, C. tropicalis, C. guilliermondii, and C. lusitaniae (107).
This increase was also observed for C. krusei isolates between the years 1997 and 2007 (107).
Although the increases in fluconazole resistant strains were minimal, the fact that there is an
upward trend is concerning.
Various mechanisms of resistance for commonly used antifungals have been elucidated
in the recent years. For fluconazole in particular, several molecular mechanisms of resistance
spanning many Candida species have been clarified. Many of the mechanisms of resistance to
fluconazole involve modifications of the drug target (98). As mentioned earlier, the azole class of
compounds are inhibitors of the enzyme encoded by ERG11, 14α-demethylase (97). These
alterations can take the form of upregulation of ERG11, point mutations of ERG11, and
aneuploidy of chromosome 5 (98). Upregulation of ERG11 is thought to be due to gain of
function mutations in UPC2, an upstream regulator of sterol biosynthesis (111). The specificity
for which point mutations of ERG11 conferring increased fluconazole resistance seems to be
low, with 21 different point mutations observed to confer resistance in C. albicans isolates (98).
Regarding aneuploidy of chromosome 5, gain of this chromosome has been observed to increase
fluconazole resistance (112). Each of these mechanisms of fluconazole resistance have been
identified in C. albicans isolates, while upregulation of ERG11 and point mutations of ERG11
have been observed in C. parapsilosis and C. tropicalis (98). Only one of these mechanisms,
point mutations of ERG11, have been observed in the emergent Candida species, C. auris (98).
Two ERG11-independent mechanisms of fluconazole resistance in Candida species have
also been clarified. These include bypassing the ERG11 pathway, and upregulation of drug
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efflux pumps (98). Bypass of the ERG11 pathway is usually accomplished by loss-of-function
mutations in ERG3 (113). This presumably results in a minimalization of damage caused by
fluconazole (113). The mechanism of upregulating drug efflux pumps usually involves CDR1
and CDR2 of the ATP-binding cassette (ABC) family or MDR1 of the major facilitator
superfamily (MFS) class (98). Resistance is acquired because upregulation of these pumps
results in reduced cytoplasmic levels of fluconazole (98).
Bypass of the ERG11 pathway has been observed in C. albicans and C. tropicalis isolates
(98). Upregulation of both classes of drug efflux pumps has been observed in C. albicans, C.
glabrata, and C. parasiplosis. C. krusei isolates have been observed to have upregulation of the
ABC transporters, but not the MFS transporters. In contrast, C. tropicalis isolates have been
observed to have upregulation of the MFS transporters, but not the ABC transporters (98).
In addition to reports of increased frequency of fluconazole resistance, an increase in
frequency of echinocandin resistance in Candida species has been reported (55, 114, 115).
Although the frequencies of echinocandin resistance remain relatively low, this has the potential
to be a great clinical concern if this upward trend continues (105). Adding to the concern is the
fact that guidelines are now recommending echinocandins as the first choice for treatment of
various forms of candidiasis due to its effectiveness, low drug toxicity, and minimal drug-drug
interactions.
As stated earlier, the echinocandin class of compounds functions by inhibiting β-1,3
glucan synthase, resulting in reduced cell wall integrity (108). The major subunit of this enzyme
is encoded by FKS1 and resistance mechanisms involve point mutations of this gene (116, 117).
Indeed, various point mutations of FKS1 have been observed in various Candida species. The
Candida species isolates that display increased echinocandin resistance due to mutations in FKS1
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include: C. albicans, C. glabrata, C. krusei, C. tropicalis, and C. dubliniensis (118). Resistance
has also been observed in C. glabrata resulting from point mutations in FKS2, a paralog of FKS1
(55).
Resistance to polyenes is predicted to be rare, however, there have been reports of
resistance to Amphotericin B in various Candida species (70, 74). It is postulated that resistance
to Amphotericin B is caused by changes in cell membrane composition due to mutations of ERG
genes (119, 120).
Although drug resistance can cause complications during antifungal therapy, the low
frequency of echinocandin resistance observed should quell major concerns regarding drug
resistance. It will be very important to continue conducting surveys for increased resistance,
though, since the trends, as of now, point upward. Additionally, having more antifungals
available will allow healthcare workers to better treat individuals affected by fungal infections,
thus it is imperative to continue the development of novel antifungals.
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INTRODUCTION
Fungal infections represent a growing human health concern. Candida species are the
causative agents of the most prevalent fungal infections in the U.S., causing superficial and
systemic candidiasis, the latter associated with high mortality rates (2, 121). Additionally,
Candida species are the fourth most common cause of nosocomial bloodstream infections in the
U.S (11). The therapeutic agents used to treat superficial and systemic candidiasis are mainly
limited to three classes of compounds: the polyenes, azoles, and echinocandins (87). The azoles
are one of the most prescribed antifungal agent even though some strains of C. albicans and C.
glabrata have acquired resistance to this class of compounds while other Candida species, such
as C. krusei, are innately azole-resistant at therapeutic concentrations (98, 122). In contrast, the
polyenes remain highly effective, but drug toxicity has limited their usage (87, 121).
Echinocandins, the most recent addition to the antifungal arsenal, have shown to be effective
with minimal drug toxicity and thus a promising alternative to the former classes (87, 121).
However, an increase in acquired resistance by C. glabrata has been reported, likely due to an
increase of usage (123-125). The limitations of each class of compounds and the present and
future concerns of drug resistance have brought to the forefront efforts to develop new
antifungals effective against Candida species and other pathogenic fungi.
One area of research that has garnered interest as a source for novel antimicrobial agents
is the utilization of naturally occurring antimicrobial peptides (AMPs). AMPs have been
identified in a wide range of organisms, including plants, invertebrates, and vertebrates (126).
These peptides often serve as first line of defense against invading pathogens and are a vital
component of innate immune systems (127, 128). One characteristic that has led to the
excitement surrounding these peptides is the broad range of activity they display. AMPs have
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shown to have antibacterial, antifungal, antiviral, and antitumor activity (129). In addition to the
broad range of activities, antimicrobial peptides display varying mechanisms of action (129).
Regarding antimicrobial peptides with antifungal properties, several mechanisms of action
(MOA) have been proposed, including: membrane permeabilization, mitochondrial
perturbations, initiation of apoptosis, osmotic stress, and DNA damage (130-134). Due to the
unique MOAs presented by antimicrobial peptides, it raises the question whether some of these
could have synergistic effects with traditional antifungal agents during combination therapy and
indeed, synergistic effects have been reported between AMPs and antifungal agents (135, 136).
AMPs share the issues many promising pharmaceuticals have, including: cytotoxicity,
expensive or laborious production, low activity, and low stability (137, 138). One increasingly
popular technique used to minimize or circumvent these issues is the design and synthesis of
AMP analogs (137, 138). Common ways of manipulating natural AMPs include shortening of
the peptide, amino acid substitution, and lipid tagging (138). Shortening of AMPs can not only
reduce the cost of production but also increase activity (137, 138). A notable example of
increasing activity by shortening an AMP is dhvar4, a Histatin 5 derived peptide (139). Amino
acid substitution has shown to be able to improve activity and stability (140, 141). Improvement
of activity is usually accomplished by substituting amino acids to increase hydrophobicity or
cationicity whereas improvement of stability is accomplished by the introduction of D-amino
acids or bulky side chains (138). It is thought that lipid tagging improves activity by increasing
membrane association (138).
Studies from our laboratory have identified a small histatin 5-derived analog, KM29 (YK-R-K-F-K-R-K-Y), that yields significant fungicidal activity and is active against a variety of
Candida species (142). Structure-function experiments were performed to identify the minimal
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sequence (Y-K-R-K-F; KM Motif) needed to retain fungicidal activity (142). Moreover, a review
of the literature revealed the presence of this motif in nearly every published Histatin 5-derived
analog. This sequence was used to generate peptide variants with enhanced antifungal activity
(142). Additionally, KM29 displayed minimal red blood cell hemolysis (142). These data denote
the potential of KM29 to be utilized as a cost-effective antifungal therapeutic agent. Here we
extend these studies by using S. cerevisiae as a genetically tractable model to elucidate the
mechanism of action of KM29. We conclude by showing the conservation of MOA in the
clinically relevant Candida albicans.
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MATERIALS AND METHODS
Yeast strains
All experiments involving S. cerevisiae were carried with strain BY4741 (MATa his3∆1 leu2∆0
met15∆0 ura3∆0) (143). In instances when mutant strains were used, these were obtained from
the MATa haploid deletion library in the BY4741 background (144). Where indicated,
experiments involving C. albicans were carried out with SC5314, LLF100 (SN152), or LLF088
(SN152). LLF100 and LLF088 originate from the SN152 strain. LLF100 is a prototrophic wild
type control strain and LLF088 carries a homozygous deletion for COQ3 (145). Unless
indicated, strains were grown on standard YPD medium (1% yeast extract, 2% peptone, 2%
glucose). Plates contained 2% agar (Difco).
Genome wide screen for mutants with increased resistance or increased sensitivity to
KM29
Mutant strains from the S. cerevisiae MATa haploid deletion library were collected from frozen
stocks and inoculated on OmniTray (Nunc) YPD plates for 48 hours at 30° C. Deletion strains
were then transferred to 150 µl of sterile distilled water (diH20) in 96-well plates via 96-well pin
replicators. The average OD600 of all the wells was calculated with a spectrophotometer (Eon,
BioTek) and the cell count of the average OD600 was quantified with a hemocytometer. Cell
density of individual wells was adjusted by adding more cells or adding more diH20 to achieve
the average OD600. Cells were diluted in diH20 and added to a 96-well plate containing 0.125X
SD+Trp (synthetic dextrose + 400 µm Tryptophan) supplemented with glucose (pH 6.0), 4 µm or
2 µm KM29, and 50 µg/ml resazurin (Sigma) for a final concentration of 5.25x104 cells/ml. 4
µm KM29 was used to test for increased resistance; at this concentration wild-type cells display
no growth and growth of a deletion mutant would indicate increased resistance. 2 µm KM29 was
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used to test for increased sensitivity; at this concentration wild-type cells display growth and lack
of growth of a deletion mutant would indicate increased sensitivity. Each plate contained a well
with a wild-type control (BY4741) and a negative control with no cells. Plates containing 4 µm
KM29 were incubated for 43-48 hours and plates containing 2 µm were incubated for 29-32
hours at 30° C. After incubation, plates were analyzed for color change of the pH indicator,
resazurin. Resazurin has a blue color at pH 6.0 and as the pH drops, due to by-products of
fermentative growth in this case, transitions to orange/red. Resorufin, the acid-form of resazurin,
can also be fully-reduced to form the colorless dihydroresorufin. Wells were analyzed for a
transition from blue to orange/red/colorless and labeled as having growth or no growth. Each
plate was repeated in duplicate for each concentration of KM29 and deletion mutants that
showed growth or no growth in both trials were denoted as having increased resistance or
increased sensitivity to KM29.
KM29 localization in S. cerevisiae and C. albicans
S. cerevisiae or C. albicans SC5314 was grown overnight in 5 ml of liquid YPD at 30° C or 37°
C, respectively. The cell count of a 1:100 dilution of an overnight culture was quantified using a
hemocytometer to determine the cell density. Cells from the overnight culture were pelleted and
resuspended in distilled water (diH20) to a final concentration of 1x108 cells/ml. Either KM29FITC, MitoTracker DeepRed (Molecular Probes), or both concurrently were added to cell
suspensions for final concentrations of 5 uM KM29-FITC and 500 nM MitoTracker DeepRed. 3
µM KM29-FITC was used for C. albicans experiments to minimize oversaturation. MitoTracker
DeepRed is a mitochondria specific stain that constitutively localizes to mitochondria in live
cells. After incubation for 30 minutes at 30° C, cells were washed 2 times in 1X phosphate
buffered saline (PBS) and visualized with a fluorescence microscope (Zeiss AxioImager M1). A
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GFP filter (Zeiss set 38) was used to observed KM29-FITC localization and a Cy5 filter (Zeiss
set 50) was used to observed MitoTracker DeepRed localization.
Fungicidal activity of KM29 against S. cerevisiae and C. albicans
Fungicidal activity of KM29 was probed using microdilution plate assays. S. cerevisiae was
grown for 48 hours on YPD plates at 30° C. Single colonies of S. cerevisiae were resuspended in
1 ml of 5 mM sodium phosphate (NaP) buffer, pH 7.4. Cell counts were then calculated using a
hemocytometer. Afterwards, cells were diluted in the same buffer to reach a cell density of
1.5x105 cells/ml. Cell suspensions were made by mixing 20 µl cells and 20 µl of peptide
dissolved in 5mM NaP buffer. Final peptide concentrations used were 1, 2.5, and 5 µM. These
suspensions were incubated in a shaking incubator at 220 rpm for 2 hours at 30° C. Peptide
reactions were stopped by adding 360 µl of yeast nitrogen base (YNB). 40 µl of cell suspension
added to 100 µl of YNB was spread onto YPD plates with 6-8 glass beads and incubated for 48
hours at 30° C. Colony forming units (CFUs) were counted and percent survival was calculated
as (colonies from suspension with peptide)/(colonies from suspension without peptide)x100.
Each assay was repeated a minimum of three times.
This protocol was modified slightly to determine fungicidal activity of KM29 against C. albicans
LLF100 and LLF088. Initially, C. albicans was grown for 24 hours on YPD at 37° C. Due to C.
albicans increased sensitivity to KM29, 10 mM NaP buffer was used instead of 5 mM in all
cases, and final peptide concentrations of 0.5, 1, and 2.5 µM were used instead of 1, 2.5, and 5
µM used for S. cerevisiae. These two changes allowed us to maintain a survival curve that
approximately displayed 75, 50, and 25% survival, respectively. Plates were incubated for 24
hours at 37° C.
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In instances that petite mutants were analyzed using microdilution assays, all incubation times
for plates were extended by 24 hours to account for the slow growth of these mutants.
Measurement of ROS production
S. cerevisiae was grown overnight in 5 ml liquid YPD at 30° C. Cells from the overnight culture
were resuspended in 5 mM sodium phosphate buffer (NaP) pH 7.4 to reach a cell density of
~OD600 1.2 and KM29 was added to final concentrations of 56 or 139 µm. After incubation for 1
hour at 30° C, cells were washed and resuspended in 1X phosphate buffered saline (PBS).
Dichlorofluorescein diacetate (DCFHDA; SIGMA) or dihydroethidium (DHE; Molecular
Probes) was added to final concentrations of 10 µm or 1 µm, respectively. DCFHDA and DHE
are fluorescent probes that upon oxidation by reactive oxygen species, transition to highly
fluorescent molecules. For DHE related fluorescence, ethidium requires intercalating within
DNA to fluoresce. These solutions were incubated for 30 minutes at 30° C in the dark in a roller
drum at medium speed. Cells were then transferred to a black 96-well plate (Costar 3603) and
fluorescence intensity was measured with a fluorescence spectrophotometer (Eon, BioTek).
Transition from DCFHDA to DCF was measured with λex 504 nm and λem 529 nm, and transition
from DHE to ethidium was measured with λex 518 nm and λem 606 nm. A sample of the cells was
also visualized with a fluorescent microscope (Zeiss AxioImager M1). DCF fluorescence was
viewed with a GFP filter (Zeiss set 38) and ethidium fluorescence was viewed with a Rho filter
(Zeiss set 20).
Measurement of ROS-induced cell death
S. cerevisiae was grown overnight in 5 ml liquid YPD at 30° C. Cells from the overnight culture
were resuspended in fresh YPD to reach a cell density of ~OD600 1.2. N-acetyl cysteine (NAC;
SIGMA) was added for a final concentration of 50 mM and incubated for 2 hours at 30° C in a
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roller drum at medium speed. For cell suspensions without NAC treatment, a concomitant
volume of diH2O was added. After incubation, cells from the two experimental groups were used
in microdilution killing assays as described earlier.
Assessment of mitochondrial network morphology and mitochondrial membrane potential
To assay mitochondrial network morphology and mitochondrial membrane potential (MMP), we
employed the Mitoloc system (146). The MitoLoc system is a microscopy-based dual
fluorescence system used to assay in vivo mitochondrial membrane potential (MMP) and
mitochondrial network morphology. It consists of a plasmid constructed with GFP-tagged,
preSU9 of Neurospora crassa, and mCherry-tagged, preCOX4 of S. cerevisiae; preSU9 localizes
to mitochondria independent of MMP, thus robustly labeling mitochondrial structures, while
preCOX4 localization to mitochondria is MMP dependent (146). Measuring colocalization
between the two markers allows for single cell quantification of MMP on a pixel-by-pixel basis.
S. cerevisiae BY4741 cells were transformed with pMitoloc using a one-step yeast
transformation protocol with the addition of a 4 hour recovery in YPD and then plated on YPD
containing 100 µg/ml of nourseothricin (CloNat, Werner) for plasmid selection (147). One of the
resulting transformants was used to inoculate 5 ml of liquid YPD+CloNat and grown overnight.
A 1:100 dilution of the overnight culture was made, and the cell count of this dilution was
quantified using a hemocytometer. Cells were pelleted and resuspended in 5 mM sodium
phosphate buffer (NaP) pH 7.4 to reach a cell density of 1x108 cells/ml. Additionally, either
carbonyl cyanide m-chlorophenyl hydrazine (CCCP; SIGMA) or KM29 was added to the cell
suspensions for final concentrations of 15 µm and 166 µm, respectively. After incubation for 3
hours at 30° C, cells were washed 2 times in 1X phosphate buffered saline (PBS) and fixed with
10% formaldehyde (Mallinckrodt) for 30 minutes at room temperature. Afterwards, cells were

23

washed once with 1X PBS and viewed with a fluorescence microscope. The GFP filter (Zeiss set
38) was used to observe the MMP independent mitochondrial marker and the Cy5 filter (Zeiss
set 50) was used to observe the MMP dependent mitochondrial marker. Image stacks using Zspacing of 200 nm were acquired with Zeiss AxioVision image analysis software and processed
by deconvolution. Image stacks were then analyzed using the ImageJ plugin yeast_correlation.
KM29 uptake in S. cerevisiae and C. albicans
S. cerevisiae or C. albicans (LLF100 and LLF088) was grown overnight in liquid YPD culture at
30° C or 37° C, respectively. A 1:100 dilution of the cell culture was made in either 5 mM
sodium phosphate (NaP) buffer pH 7.4 for S. cerevisiae or 10 mM NaP buffer for C. albicans.
Cell counts were quantified using a hemocytometer. Cells from the original culture were pelleted
and resuspended in NaP buffer for a final cell concentration of 1x108 cells/ml and 5 µm KM29FITC. Cell-peptide suspensions were incubated for 30 minutes at 30° C in a roller drum at
medium speed. Cells were washed twice and resuspended in 1X phosphate buffered saline
(PBS). 200 µl of these cells were added to a black 96-well plate and fluorescence intensity was
quantified in a fluorescence spectrophotometer at λex 495 nm and λem 519 nm. Additionally, cells
were examined with a fluorescence microscope (Zeiss AxioImager M1) with a GFP filter (Zeiss
set 38).
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RESULTS
Genome wide screen for mutants with increased resistance or increased sensitivity to
KM29. In an effort to discern the antifungal mechanism of action of KM29 we took advantage
of the S. cerevisiae non-essential deletion library and devised a modified MIC assay that would
allow us to identify mutants that conferred either increased sensitivity of resistance to the
peptide. The MATa haploid mutant library in the BY4741 background was screened for
increased resistance and increased sensitivity to KM29 compared to the wild-type. Mutants with
increased resistance were identified by the ability to grow in the presence of a KM29
concentration that completely inhibited wild-type growth, while mutants with increased
sensitivity were identified by the inability to grow in the presence of a KM29 concentration that
did not inhibit wild-type growth. Of the ~4900 mutants tested, 1,360 displayed increased
resistance in duplicate while 508 displayed increased sensitivity in duplicate. These mutants
represented ~27 and ~10% of the total number of mutants screened, respectively.
Two clustering methods were carried out on the mutants to identify any patterns
associated with increased resistance or increased sensitivity. The first clustering analysis
employed was GO annotation from the SGD database (Table 1A & 2A). GO annotation grouping
is based on annotations derived from published experiments in the GO database. ORF lists for
mutants that displayed increased resistance or sensitivity were inputted into the Yeast GOSlimMapper and grouped by “Process”. The second clustering analysis employed was FunSpec
(Table 1B & 2B). FunSpec clustering is derived from published experiments in the GO database
as well as the MIPS database. ORF lists for mutants that displayed increased resistance or
sensitivity were inputted into FunSpec and grouped based on various parameters such as
function, process, localization, protein complexes, phenotypes, etc.
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To analyze the results of the GO annotation clustering, the normalized genome frequency
(cluster number/genome number x 100) was calculated for each Biological Process and ranked in
descending order. As shown in Table 1A, several functional categories were enriched in the
mutants that displayed increased resistance. Interestingly, a few biological processes relating to
mitochondrial function were among the most enriched, including: mitochondrial translation,
cellular respiration, and mitochondrion organization. These categories had normalized genome
frequencies of 37, 35, and 31%, respectively. Amino acid transport and generation of precursor
metabolites and energy were also heavily enriched processes. Surprisingly, sporulation had the
third highest normalized genome frequency at 35%.
Further quantification of the categories enriched by the resistant mutants supported the
findings by the GO annotation clustering (Table 1B). In every category, mitochondrial related
annotations were the most significantly represented. Revealing is the fact that a respiratory
deficiency phenotype was one of the most significantly enriched annotations. This may denote
the underlying reason for why so many mitochondrial mutants were uncovered. Understanding
the relationship between mitochondria and KM29s mechanism of action served as the basis for
the rest of the studies presented.
Analysis of the mutants with increased sensitivity to KM29 by GO annotation clustering
revealed invasive growth in response to glucose limitation, organelle inheritance, and
cytoplasmic translation as the functional categories with the three highest normalized genome
frequencies (Table 2A). These categories had normalized genome frequencies of 27, 23, and
22%, respectively. Interestingly, endosomal transport and vesicle organization had high
normalized genome frequencies as well. Analysis of these mutants by FunSpec revealed an
increased significance of annotations relating to endosomal transport and vacuolar function than
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the GO annotation clustering revealed (Table 2B). In every category, an annotation relating to
the endosome was significantly enriched. Additionally, translation related annotations were also
present. Interestingly, the divalent cation and heavy metal sensitivity phenotype was significantly
enriched by the mutants that displayed increased sensitivity to KM29.
KM29 localizes to mitochondria in S. cerevisiae and C. albicans. Among the mutants that
displayed increased KM29 resistance there was a prevalence of mitochondrial annotations that
prompted us to investigate the relationship between mitochondrial function and the mechanism
of action of KM29. To study whether there was a direct association between KM29 and
mitochondria, the internal localization of KM29 was investigated with fluorescence microscopy.
S. cerevisiae and C. albicans cells were incubated with 5μM and 3μM KM29-FITC, respectively,
and 500nM MitoTracker DeepRed concurrently. Preliminary work showed that labeling of
KM29 with FITC did not affect the fungicidal activity of KM29, assessed by minimum
inhibitory concentration assays (data not shown). KM29-FITC localized in a punctate pattern
with some cells displaying increased localization near the cell periphery in S. cerevisiae and C.
albicans (Fig. 1). In both organisms, partial colocalization occurred between KM29-FITC and
the mitochondria-specific stain, MitoTracker DeepRed. These data indicate that KM29 is directly
associated with mitochondria once internalized by S. cerevisiae and C. albicans even though
some KM29 remains cytosolic, perhaps due to interaction with other cellular targets.
KM29 fungicidal activity is dependent on Electron Transport Chain function. The results
from the genome wide screen and KM29 localization study demonstrated mitochondria play a
role in the mechanism of action of KM29 and led us to hypothesize that the process of aerobic
respiration plays an intimate role in KM29 fungicidal activity. To test this hypothesis, as well as
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confirm the results of the genetic screen, we performed microdilution killing assays with S.
cerevisiae deletion mutants encompassing the Electron Transport Chain (ETC) complexes.
Ndi1, NADH:ubiquinone oxidoreductase, is the only subunit of the yeast Complex I,
responsible for transferring elections from NADH to ubiquinone in the respiratory chain (148).
The ndi1∆ strain didn’t show significantly increased resistance to KM29 in either the
microdilution killing assays or the genome wide screen (Fig. 2). We next assayed Sdh2, a subunit
of succinate dehydrogenase and a constituent of Complex II, which receives electrons from
FADH2 (148). The sdh2∆ strain showed significantly increased resistance to KM29 and
likewise, was uncovered to have increased resistance in the genome wide screen. It is important
to note that minor amounts of respiration can still occur in single deletion mutants of each of
these, and therefore, this may reflect the ability of KM29 to still have fungicidal activity against
single deletion mutants of these complexes.
The next two complexes in the ETC series, Complex III (cytochrome bc1 complex) and
Complex IV (cytochrome c oxidase), are essential for respiration (148). A deletion of the genes
encoding essential subunits in each of these complexes (qcr7∆, cox9∆, and cox12∆) results in
significantly increased resistance to KM29, almost reaching 100% survival (Fig. 2). The three
mutants also displayed high resistance in the genome wide screen. This increased resistance is
presumably due to the complete lack of respiration in these mutants. Qqcr10∆ is a non-essential
subunit in the cytochrome bc1 complex; it is the last subunit to be assembled to the complex but
is not required for respiratory growth (149). According to our hypothesized relationship between
aerobic respiration and KM29 mechanism of action, we would expect a qcr10∆ strain not to be
resistant to KM29 since it is still able to respire. Indeed, qcr10∆ cells were sensitive to KM29,
not significantly different from the wild-type strain. Interestingly, the qcr10∆ mutant was also
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identified in the screen for increased resistance to KM29, which we interpret as a false positive,
likely a result of the extreme sensitivity of the MIC assay detecting slight perturbations in growth
rates. Altogether these results confirm our hypothesis that KM29 fungicidal activity is dependent
on ETC function; cells defective in respiration are more resistance to KM29.
Reactive oxygen species (ROS) production in S. cerevisiae. The above results implicating the
ETC in KM29 activity raise the possibility that perturbations of the ETC may be involved in
initiating/causing cell death. One of the most common outcomes of aberrant ETC function is
ROS formation. Two, common fluorescent probes suitable for measuring ROS formation include
dichloroflourescein diacetate (DCF-DA) and dihydroethidium (DHE). To measure ROS
formation induced by KM29, we preloaded cells with either 10μM DCF-DA or 1μM DHE and
subsequently treated them with increasing concentrations of KM29. ROS formation was
analyzed with fluorescent spectrophotometry and fluorescent microscopy. KM29 induced ROS
formation regardless of the probe used to test it. When measured with 10μM DCF-DA ROS
formation increased upon treatment with KM29 in a concentration dependent manner (Fig.
3A,B). However, when measure with 1µM DHE, the significant increase in ROS formation
appears to reach a plateau with 56µm KM29 (Fig. 3C,D). This is presumably the maximum level
of ROS detected due to the minimal concentration of DHE that was used to preload cells. As
suggested, 1μM DHE was used to avoid artifacts caused by excessive DHE (150).
To assess whether there is a correlation between KM29-induced, ROS formation with
KM29 fungicidal activity, cells were preloaded with n-acetyl cysteine (NAC), a known ROS
scavenger, and subsequently used in microdilution killing assays. NAC treatment completely
abolished KM29-induced, ROS formation but did not increase survival by a concomitant
amount; NAC pretreatment led to ~15% increase in survival at each KM29 concentration (Fig.
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3E, 3F). This is consistent with the findings from the genome wide screen as only one gene
associated with the oxidative stress response was found to be more sensitive to KM29 when
deleted. These results indicate that ROS formation contributes to KM29 fungicidal activity, but it
is unlikely the only source of damage caused by KM29.
KM29 causes depolarization of the mitochondrial membrane potential and mitochondrial
fragmentation in S. cerevisiae. To explore other mitochondrial perturbations possibly caused by
KM29, we employed the MitoLoc system to assay in vivo mitochondrial membrane potential
(MMP) and mitochondrial network morphology. A plasmid expressing GFP-tagged preSU9 and
mCherry-tagged preCOX4 was introduced into wild-type and qcr7∆ strains. preSU9 localizes to
mitochondria independent of MMP, thus robustly labeling mitochondrial structures, while
preCOX4 localization to mitochondria is MMP dependent (146). Colocalization of the two
markers allows for single cell quantification of MMP. Transformed wild-type cells were treated
with either a non-lethal concentration of KM29 or 15μM CCCP (as a positive control for MMP
disruption). The Pearson Correlation Coefficient was significantly decreased when cells were
treated with either KM29 or CCCP, indicating a decrease in MMP (Fig. 4A). We included qcr7∆
cells as an additional control. Since these cells are respiratory-deficient we expected the Pearson
Correlation Coefficient to be very low, as indeed was the case. In addition to lowering MMP,
KM29-treated cells displayed clear mitochondrial fragmentation when compared with untreated
cells (Fig. 4B). Also noteworthy is the fact that mitochondrial fragmentation did not occur in
neither the CCCP treated cells nor the transformed qcr7∆ cells. These data show that the
physiological status as well as the structure of mitochondria is significantly affected by KM29
treatment, consistent with KM29 localization to mitochondria and the ETC involvement in its
fungicidal activity.
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Respiratory status inversely regulates KM29 uptake in S. cerevisiae. The results thus far
revealed mitochondria as one of the sites for KM29 induced perturbations, however, these
findings have not clarified the mechanism by which respiratory deficiency confers cells nearly
complete resistance to KM29. To investigate whether the resistance associated with respiratory
deficiency is a consequence of a cytoplasmic effect or could also be affecting uptake of the
peptide we measured KM29-FITC uptake in the ETC mutants presented earlier. Surprisingly, the
respiratory capability of each mutant inversely regulates KM29 uptake (Fig. 5), i.e. mutants that
are completely respiratory deficient have minimal KM29 uptake and mutants that have partially
decreased respiratory capabilities have intermediate levels of KM29 uptake. The decrease in
KM29 uptake is reflected in the killing assays presented in Fig. 2. We also looked at KM29
uptake and KM29 fungicidal activity in ATP synthase mutants. Since ATP synthase is the final
complex involved in energy production from aerobic respiration, we hypothesized that these
mutants would be deficient in KM29 uptake. Indeed, mutants of ATP synthase showed to have
minimal KM29 uptake and ~100% survival when treated with 2.5μM KM29 (Fig. 5). Since ATP
synthase isn’t involved in electron shuttling nor establishment of the proton gradient, this raises
the intriguing possibility that the underlying reason KM29 resistance is observed in respiratory
deficient cells is due to reduced ATP production.
Respiratory status inversely regulates KM29 uptake and killing in C. albicans. The purpose
of the genetic screen using the available genome-wide deletion collection in S. cerevisiae was to
use this as a subrogates species to learn about the killing mechanism used by KM29 in Candida
species. Therefore, we asked if our findings in S. cerevisiae would extend to the clinically
relevant Candida albicans. To do this we analyzed KM29 uptake and killing in a coq3∆ mutant
of C. albicans. COQ3 encodes an enzyme involved in the synthesis of mitochondrial ubiquinone.
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Ubiquinone shuttles electrons from Complex I & II of the ETC to Complex III (151). Absence of
ubiquinone results in respiratory deficiency, thus we would expect KM29 uptake and killing to
be decreased in this mutant when compared to the wild-type. The coq3∆ mutant had significantly
decreased KM29 uptake and this is reflected in the survival when both the mutant and wild-type
were treated with 1μM KM29 (Fig. 6A). In addition, the S. cerevisiae coq3∆ mutant shared this
phenotype (Fig. 6B). Interestingly, when we compared KM29 uptake between S. cerevisiae and
C. albicans wild-type cells (Fig. 6B & 6E), C. albicans had substantially higher KM29 uptake,
which correlates with the increased sensitivity of C. albicans to KM29.
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DISCUSSION
The goal of this study was to elucidate the fungicidal mechanism of action of the novel
antifungal peptide, KM29, inspired on the naturally occurring histatins. We initially developed
and performed an unbiased screen of the haploid deletion collection in S. cerevisiae to identify
mutations that confer increased resistance or increased sensitivity to KM29 in an effort to
uncover genetic pathways involved in the mechanism of action of KM29. Of the ~4,900 mutants
tested, 1,360, ~27% of the total mutants displayed increased resistance while 508, ~10% of the
total mutants tested displayed increased sensitivity. We hypothesized that any biological process
implicated in increased resistance to KM29 may represent an intracellular target of the peptide,
way of entry into the cell, or alterations in the cell wall and membranes. In contrast, we
hypothesized that any biological process implicated in increased sensitivity may represent a
defense system against KM29 fungicidal effects, or alterations in the cell wall and membranes.
Although broad, these served as our basis for analyzing the results of the genetic screen.
Genetic pathways implicated in increased sensitivity to KM29
Regarding the mutants that conferred increased sensitivity to KM29, statistical analysis
with the Yeast GO-SlimMapper revealed several biological processes. Those with the most
significant representation included invasive growth in response to glucose limitation, organelle
inheritance, cytoplasmic translation, endosomal transport, vesicle organization, and protein
glycosylation. In addition, we performed a FunSpec analysis of these mutants which revealed
endosomal and vacuolar mutants to be at the intersection of these two analyses.
It is interesting that these two systems are implicated in sensitivity to KM29, as they
both have functions in degradation of cell membrane proteins (152). This process begins with
endocytosis and formation of vesicles carrying membrane components. These vesicles
coalescence to form early endosomes (152). From here, cargo in early endosomes is sorted into
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those components destined for degradation in the vacuole and those destined for the golgi in
order to be recycled (152). It is possible that upon contact with the cell membrane, KM29
induces damage on cell membrane components which signals these components to be
endocytosed and degraded. Impairment of the endocytosis system may result in accumulation of
damaged molecules on the cell membrane, thus resulting in collapse of cell membrane integrity
and eventually cell death. Likewise, impairment of the system that transports these damaged
molecules to the vacuole, or of the vacuole itself, may result in intracellular accumulation of
damaged membrane components and cause further damage. The explanation is particularly
interesting given the cationic nature of KM29 and the numerous reports of cationic molecules
interacting with membranes on various cells to induce pore formation or membrane damage
(153-155).
Vacuoles also play an important role in cellular homeostasis by storing various ions and
molecules (156). In a scenario where KM29 induces osmotic stress, the vacuole would serve to
counter this stress. Impairment of the vacuolar function, in this scenario, would lead to the cell
being less able to cope with the osmotic stress caused by KM29, thus causing increased
sensitivity. Confirmation of this would denote a conservation of mechanism of action between
KM29 and Histatin 5, the protein from which KM29 was designed, as a study found that Histatin
5 induces osmotic stress in C. albicans (157). This possibility is slightly attenuated, however, by
the low frequency for which genes categorized in the response to osmotic stress biological
process were enriched by our genetic screen.
Supporting the implication of endosomal and vacuolar function in increased sensitivity to
KM29 is the redundant categorization of endosomal-vacuolar genes into seemingly unrelated
biological processes with high normalized genome frequencies in our screen. For example,
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EMP70 is categorized in invasive growth in response to glucose limitation, as well as, endosomal
transport. It is expected that many genes, such as this one, would have differential expression and
roles in a complex process, such as invasive growth, unrelated to their basal roles within cells.
Additionally, many of the genes categorized in the organelle inheritance biological process, the
biological process with the second highest normalized genome frequency in our genetic screen,
have functions relating to endosomes and vacuoles. PEP12, VAC8, and VPS21 are some
examples of this group. Altogether, these findings led us to hypothesize KM29 may induce
cellular membrane damage and/or alterations in cellular homeostasis. Future work will be needed
to confirm this.
Genetic pathways implicated in increased resistance to KM29
Regarding the mutants that conferred increased resistance to KM29, statistical analysis
with the Yeast GO-SlimMapper revealed several biological processes. The most significant
biological processes include mitochondrial translation, amino acid transport, cellular respiration,
sporulation, mitochondrion organization, and generation of precursor metabolites and energy. In
addition, we performed a FunSpec analysis of these mutants which revealed significant
enrichment of mitochondrial related categories. We initially hypothesized that any biological
process implicated in increased resistance to KM29 may represent a cellular target, way of entry
into the cell, or alteration in the cell membrane or cell wall. We believe our results support this
hypothesis by revealing amino acid transport as a possible way of entry into the cell, and
mitochondria as a possible target for the peptide.
Amino acid transport had the second highest normalized genome frequency in our screen.
This leads us to theorize that KM29 may hijack various amino acid permeases and transporters
as a way of entry into the cell. In this scenario, it would make sense for a deletion of one of the
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permeases to confer increased resistance to KM29 since there would be less cytoplasmic
accumulation of KM29 and therefore, less cellular damage. To analyze whether there is
specificity for the transport mechanisms KM29 can hijack, we looked closer at the genes
categorized in this group. Many different amino acid transporters were present, including: a
leucine permease (BAP2), an arginine permease (CAN1), a proline permease (PUT4), a
tryptophan and tyrosine permease (TAT2), a cysteine transporter (YCT1), and a general amino
acid transporter (VBA5). This reveals that KM29 entry into cells may be promiscuous and
lacking specificity; KM29 may simply take advantage of any entry mechanism. A GABA
permease (UBA4), was also present in this category, reflecting another transport mechanism
KM29 may use for entry into cells. These data open up the intriguing possibility this nine-amino
acid cationic peptide may interact with highly specific but unrelated membrane transporters in a
non-specific manner to enter the cell. Alternatively, the effect is indirect; cells lacking certain
transporters may undergo changes on the plasma membrane that affects permeability to KM29.
As part of our initial hypothesis, we postulated that biological processes implicated in
increased resistance to KM29 would represent a cellular peptide target. Our reasoning behind
this hypothesis was that if a cellular peptide target is deleted or impaired the cellular drug, then
KM29 would be unable to induce damage, thereby increasing survival. Our screen identified the
mitochondria as a drug target of KM29, as a myriad of genes relating to mitochondria and
mitochondrial function were found to increase resistance when deleted. Four of the six biological
processes with the highest normalized genome frequencies were related to mitochondrial
function, including: mitochondrial translation, cellular respiration, mitochondrion organization,
and generation of precursor metabolites and energy. Additionally, the FunSpec analysis of the
mutants with increased resistance revealed an enrichment for mutants with a respiratory
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deficiency phenotype, which may denote the process of respiration as being a specific source of
KM29-induced damage. Consequences of impairment of respiration would include reactive
oxygen species (ROS) production and decrease in ATP levels, both of which would have adverse
effects on cells.
The possibility of mitochondria serving as the cellular target of KM29 is exciting. Several
studies have highlighted the potential of developing antifungals that target this organelle and the
advantages associated with it (158, 159). Among these advantages include the crippling damage
mitochondrial perturbations incur on yeast cells due to the critical cell functions this organelle is
involved in (158, 159). Additionally, many of the fungal mitochondrial factors that could be used
as potential drug targets do not have close orthologs in humans, which would reduce drug
toxicity (158). Mitochondrial dysfunction has also been implicated in hypersusceptibility to
fluconazole, stressing the relevance of this organelle in the mechanism of action of antifungals
(159).
The targeting of mitochondria by KM29 may also denote a conservation of mechanism of
action between KM29 and Histatin 5. Studies have shown energized mitochondrion as the
cellular target of Histatin 5, based on the loss of mitochondrial membrane potential and
formation of ROS triggered by exposure to the peptide (160). In a broader sense, this may denote
a common mechanism by which cationic peptides work. Most studies on cationic peptides focus
on the membrane activity of these molecules, with little effort being put into understanding the
intracellular mechanisms. Further exploration on this aspect will be of general relevance to
continue developing these molecules as antifungals of therapeutic value.
Based on these data, we propose KM29 to have a multi-step mechanism of action
following these sequence of events: KM29 entry into the cell via interaction with the plasma

37

membrane resulting in pore formation, and non-specific opportunistic use of plasma membrane
transport mechanisms, cellular damage caused by KM29 interacting with the plasma membrane,
followed by targeting to the mitochondria, once inside the intracellular compartment, resulting in
perturbation of mitochondrial function. The possible multi-faceted mechanism by which KM29
could induce cell death makes this peptide an interesting antifungal agent as this would make it
more difficult for pathogenic yeast to acquire drug resistance. Future studies will be needed,
however, to clarify the exact roles of the genetic pathways implicated in increased resistance and
increased sensitivity to KM29 in this peptides mechanism of action.
KM29-induced mitochondrial pertubations
To follow up on our proposed mechanism of action, we focused on the role of
mitochondrial function in KM29 fungicidal activity. Our observation of KM29 localization to
mitochondrion, as well as the impairment of the electron transport chain conferring increased
resistance to KM29, supports our proposed mechanism. The finding that KM29 localizes to
mitochondrion is interesting, as an independent study found that the cellular target of Histatin 5
to be the mitochondrion (160). Although this group proposes the localization of Histatin 5 to
mitochondria to be due to structural resemblances between Histatin 5 and mitochondrial
presequences, we do not believe this to be the case for KM29. An explanation for KM29’s
localization may be the cationic nature of this peptide. It is possible that KM29 localization to
mitochondria may be electrostatic-dependent. The proton gradient formed across the inner
mitochondrial membrane in actively respiring cells may serve as an attractant for KM29. This
explanation is supported by other work studying the actions of cell penetrating peptides and
cationic antibacterial peptides (155). This group proposed that the toxicity of these peptides was
dependent on large membrane potentials. For future studies, it would be fruitful to test this
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possibility by depolarizing the MMP and observing if KM29-FITC intracellular localization is
affected by this. If the MMP is an attractant for KM29, we would expect prior depolarization to
inhibit KM29 localization to mitochondria. Additionally, it would be interesting to examine how
this might affect KM29 fungicidal activity and would provide confirmation of mitochondria
serving as a site of damage.
We also observed KM29 to induce concentration-dependent ROS formation. This finding
may denote conservation of mechanism between KM29 and Histatin 5, as it has been reported
Histatin 5 could induce ROS formation, and this ROS formation was strongly correlated with
cell death (161). However, there is controversy surrounding the role of ROS in Histatin 5
mechanism of action as a separate group did not observe ROS formation due to Histatin 5
exposure (162). In our case, KM29-induced ROS formation was not strongly linked with cell
death, as pretreatment with a ROS scavenger prior to exposure to KM29 only increased survival
by ~15%. This is incongruent with our finding that complete respiratory deficiency confers
nearly 100% resistance to KM29, thus eliminating the possibility that ROS formation is the
predominate cause of cell death. Although ROS formation did not appear to play a major role in
KM29 fungicidal activity against S. cerevisiae, it is possible KM29-induced ROS formation may
adversely affect C. albicans more substantially. The Crabtree effect of S. cerevisiae, presented
by the ability to ferment in the presence of high glucose levels and repression of respiration, is
quite different from the Crabtree negative C. albicans. Thus, optimal growth of C. albicans relies
more heavily on cellular respiration (163, 164). The increased cellular respiration of C. albicans
may exacerbate KM29 ability to cause ROS production. Along this line, it will be interesting in
future studies to examine how KM29-induced ROS formation affects different pathogenic yeasts.
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Determining the status of mitochondria requires analyzing both MMP and mitochondrial
network morphology, a complex endeavor due to these two variables not being coupled to one
another (146, 165, 166). We observed KM29 to induce depolarization of mitochondrial
membrane potential (MMP) and mitochondrial fission. This could be a sign of mitochondrial
damage, as the process of mitochondrial fission has been shown to protect healthy mitochondria,
and to cause degradation of damaged mitochondria (167, 168). However, it is also possible that
KM29-induced mitochondrial fission simply occurred due to loss of MMP, as rho- have been
shown to have fragmented mitochondria (146). Additionally, our observation is consistent with
our finding that ROS formation did not play a major role in KM29 fungicidal activity. H2O2, a
known inducer of oxidative stress, has been shown to induce mitochondrial fragmentation
independent of MMP depolarization (146). This is in contrast with what we observed with
KM29. Although these findings do not show direct damage to mitochondria caused by KM29, it
is possible that depolarization of MMP caused by KM29 may indirectly affect the health of the
cell by blocking the function of cellular respiration. The final step in cellular respiration is the
utilization of the proton gradient formed in the previous steps by ATP synthase to produce ATP
from ADP and Pi. Without a proton gradient, ATP synthase would not be able to synthesize
ATP. As mentioned earlier, S. cerevisiae is Crabtree positive thus it is logical to assume this
organism wouldn’t be affected by loss of mitochondrial function under fermentative conditions,
however, this doesn’t wholly preclude the loss of mitochondrial ATP to adversely affect the cell.
Based on our observations, we do not believe ROS formation to be a major source of
KM29-induced damage. Instead, we conclude that KM29 localizes to the mitochondria and
inhibits respiration by depolarizing the MMP. In turn, this would negatively affect the energy
status of the cell and possibly signal the cell to undergo cell death. It is also possible that KM29
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deals direct damage to mitochondrial membranes in the process of localizing to this organelle.
This explanation could account for the mitochondrial fission we observed when analyzing
mitochondrial network morphology after exposure to KM29. In this case, mitochondrial fission
serves to protect healthy mitochondria and the signal for degradation of damaged mitochondria.
Mitochondrial fission after exposure to KM29 could indicate loss of mitochondrial integrity.
This explanation would be consistent with the active functions cationic peptides have on
membranes.
Respiratory deficiency and KM29 uptake
Clarification as to why respiratory deficiency confers cells nearly complete resistance to
KM29 was realized when we analyzed KM29-FITC uptake in various S. cerevisiae electron
transport chain mutants. We observed a nearly perfect inverse correlation between respiratory
status and KM29-FITC uptake. This indicates the role of mitochondrial function in KM29
fungicidal activity to be two-fold: to regulate KM29 uptake and to serve as a site for KM29induced perturbations. A possible explanation as to why mutants with varying degrees of
respiratory deficiency have reduced KM29-FITC uptake could involve the energy availability in
these strains. It has been reported that the plasma membrane proton ATPase is the major
facilitator in establishing the plasma membrane potential of the yeast cell (169). This raises the
question whether respiratory deficient mutants, because of the decrease in ATP output, have
decreased proton ATPase activity and therefore, a depolarized plasma membrane potential. If
true, this could explain the inability of KM29 to enter these mutants. This also aligns with our
explanation of KM29 localization to mitochondria being dependent upon an established MMP.
Based on this, we suggest a model of KM29 entry into yeast cells dependent upon an
electrostatic attraction, and thus, an established plasma membrane potential. A similar proposal

41

was reported by a group studying genes important for tolerance to cationic drugs (170). This
could help explain the reason why various mutants displayed increased resistance or increased
sensitivity in our genetic screen. Any mutation that affects the plasma membrane potential would
potentially affect the uptake of KM29. Along this line, it would be interesting to see if chemical
alteration of the plasma membrane potential affects KM29 uptake. Another explanation for the
reduced KM29 uptake in respiratory deficient mutants could be alterations of the plasma
membrane. Mitochondria are most commonly known for “powerhouse” functions, but they are
also involved in lipid synthesis (171). As a major constituent of the plasma membrane,
alterations in lipid synthesis could cause alterations in the plasma membrane. This in turn could
lead to alterations in KM29 entry into cells.
The inverse correlation between respiratory status and KM29 uptake was also observed
the clinically relevant C. albicans. Interesting, C. albicans SC5314 cells had more KM29 uptake
than S. cerevisiae wild type cells. A possible explanation for this could be differences in plasma
membrane composition between these two organisms. Additionally, this could be due to
differences in the Crabtree effect between the two organisms. C. albicans relies more heavily on
cellular respiration during optimal growth therefore it is reasonable to assume it has more active
mitochondria than S. cerevisiae. Since respiratory status has been shown to affect KM29 uptake,
the more active mitochondria of C. albicans could result in increased KM29 uptake. This
increased uptake in C. albicans would then be reflected in the increased sensitivity to KM29
compared to S. cerevisiae. Future work will revolve around understanding the increased KM29
uptake in C. albicans and how the metabolic differences between C. albicans and S. cerevisiae
affect KM29 fungicidal activity in these two organisms.
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In conclusion, we present initial steps in the elucidation of the mechanism of action of
KM29 in fungal cells. By understanding the mechanism of action of KM29 in S. cerevisiae we
are able to begin understanding how this peptide works against C. albicans, and provide
parameters to continue developing KM29 as a potential therapeutic agent for the treatment of
oral and systemic candidiasis. Additionally, we assert the necessity to consider alterations in
drug uptake when studying various mechanisms of resistance in medically relevant organisms.
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TABLES AND FIGURES
Table 1. Functional pathways involved in the antifungal killing activity of KM29. A
modified MIC assay was performed on the non-essential, single deletion mutants available in the
S. cerevisiae genome-wide deletion collection. The percentage of genes associated with a
specific biological process that displayed increased resistance with respect to the frequency in
the genome for specific biological processes using the Yeast GO-SlimMapper (A). A FunSpec
analysis was performed to identify functional categories enriched by the mutants that displayed
increased resistance (B).

A

B
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Table 2. Functional pathways involved in the antifungal killing activity of KM29. A
modified MIC assay was performed on the non-essential, single deletion mutants available in the
S. cerevisiae genome-wide deletion collection. The percentage of genes associated with a
specific biological process that displayed increased sensitivity (A) with respect to the frequency
in the genome for specific biological processes using the Yeast GO-SlimMapper. (B) A FunSpec
analysis was performed to identify functional categories enriched by the mutants that displayed
increased sensitivity.

A

B
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Fig. 1. Intracellular localization of KM29-FITC in S. cerevisiae and C. albicans. Fluorescent
microscopy images of S. cerevisiae wild-type cells treated with KM29-FITC (A). Fluorescent
microscopy images of a double labeling experiment. S. cerevisiae wild-typed cells were
concurrently treated with 5µm KM29-FITC and 500nm MitoTracker DeepRed
(MolecularProbes). Images show localization of KM29-FITC (left), localization of MitoTracker
DeepRed (middle), and the double labeling (right) (B). Fluorescent microscopy images of C.
albicans cells treated with KM29-FITC (C). Fluorescent microscopy images of a double labeling
experiment. C. albicans wild-typed cells were concurrently treated with 3µm KM29-FITC and
500nm MitoTracker DeepRed (MolecularProbes). Images show localization of KM29-FITC
(left), localization of MitoTracker DeepRed (middle), and the double labeling (right) (D).
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Fig. 2. Effect of Electron Transport Chain mutations on KM29 fungicidal activity.
Microdilution assay showing cell viability of S. cerevisiae wild-type and mutants from each
complex in the Electron Transport Chain at 2.5μM KM29.
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Fig. 3. KM29 concentration-dependent ROS formation. Fluorescent spectrophotometry and
corresponding fluorescent microscopy images of S. cerevisiae wild-type cells preloaded with
10μm DCF-DA (A, B) or 1μm DHE (C, D) and treated with increasing concentrations of KM29
for 30min. Microdilution assay comparing cell viability of S. cerevisiae wild-type cells
pretreated with ROS scavenger, n-acetylcysteine, and non-pretreated cells after exposure to
increasing concentrations of KM29 (E).
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Fig. 4. Mitoloc employed to assess KM29 effect on mitochondrial membrane potential and
mitochondrial morphology. S. cerevisiae wild-type cells transformed with pMitoloc were
treated with 166μm KM29 or 15μm CCCP for 3 hrs. and single cells were analyzed using ImageJ
plugin yeast_correlation. Transformed qcr7∆ (respiratory deficient) cells served as a positive
control. De co-localization of the two markers is reflected by a decrease in correlation
coefficient, PCC (A). Fluorescent microscopy images of a representative cell from each
experimental condition (B).
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Fig. 5. Comparison of KM29 uptake and killing in single deletion mutants of the yeast
ETC. Fluorescent spectrophotometry showing uptake of 5μm KM29-FITC in S. cerevisiae wildtype and mutants (A). Fluorescent microscopy images of KM29-FITC uptake in S. cerevisiae
wild-type (respiratory capable; top), qcr7∆ (respiratory deficient; middle), and qcr10∆
(respiratory capable; bottom) cells (B). Fluorescent sprectrophotometry showing uptake of 5µm
KM29-FITC in S. cerevisiae wild-type, atp5∆, and atp17∆ (C). Microdilution assay showing cell
viability of S. cerevisiae wild-type, atp5∆, and atp17∆ at 2.5μM KM29 (D).
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Fig. 6. Effect of respiratory deficiency on KM29 uptake and killing in S. cerevisiae and C.
albicans. Microdilution assay showing cell viability of C. albicans LLF100 (prototrophic wildtype) cells and C. albicans LLF088 (coq3∆; respiratory deficient) cells when treated with 1.0μM
KM29 (A). Fluorescent sprectrophotometry showing uptake of 5µm KM29-FITC in C. albicans
LLF100 (prototrophic wild-type) cells and C. albicans LLF088 (coq3∆; respiratory deficient)
cells (B). Fluorescent microscopy images of KM29-FITC uptake in C. albicans LLF100
(prototrophic wild-type) cells and C. albicans LLF088 (coq3∆; respiratory deficient) cells (C).
Microdilution assay showing cell viability of S. cerevisiae wild-type cells and coq3∆ when
treated with 2.5μM KM29 (D). Fluorescent sprectrophotometry showing uptake of 5µm KM29FITC in S. cerevisiae wild-type and coq3∆ (E). Fluorescent microscopy images of KM29-FITC
uptake in S. cerevisiae wild-type and coq3∆ (F).
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